title: Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
abstract: The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer. However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study, we developed enzalutamide-resistant prostate cancer cells in an effort to understand the mechanisms of resistance. Global gene-expression analysis showed that the steroid biosynthesis pathway is activated in enzalutamide-resistant prostate cancer cells. One of the crucial steroidogenic enzymes, AKR1C3, was significantly elevated in enzalutamide-resistant cells. In addition, AKR1C3 is highly expressed in metastatic and recurrent prostate cancer and in enzalutamide-resistant prostate xenograft tumors. LC/MS analysis of the steroid metabolites revealed that androgen precursors such as cholesterol, DHEA and progesterone, as well as androgens are highly upregulated in enzalutamide-resistant prostate cancer cells compared to the parental cells. Knockdown of AKR1C3 expression by shRNA or inhibition of AKR1C3 enzymatic activity by indomethacin resensitized enzalutamide-resistant prostate cancer cells to enzalutamide treatment both in vitro and in vivo. In contrast, overexpression of AKR1C3 confers resistance to enzalutamide. Furthermore, the combination of indomethacin and enzalutamide resulted in significant inhibition of enzalutamide-resistant tumor growth. These results suggest that AKR1C3 activation is a critical resistance mechanism associated with enzalutamide resistance; targeting intracrine androgens and AKR1C3 will overcome enzalutamide resistance and improve survival of advanced prostate cancer patients.
authors: Department of Urology, University of California, Davis, California.
authors: Chengfei
authors: C
authors: Liu
authors: Department of Urology, University of California, Davis, California.
authors: Wei
authors: W
authors: Lou
authors: Department of Urology, University of California, Davis, California. Graduate Program in Pharmacology and Toxicology, University of California, Davis, Davis, California.
authors: Yezi
authors: Y
authors: Zhu
authors: Department of Urology, University of California, Davis, California.
authors: Joy C
authors: JC
authors: Yang
authors: Department of Urology, University of California, Davis, California.
authors: Nagalakshmi
authors: N
authors: Nadiminty
authors: Departments of Nutrition and Environmental Toxicology, West Coast Metabolomics Center, University of California, Davis, Davis, California.
authors: Nilesh W
authors: NW
authors: Gaikwad
authors: Department of Urology, University of California, Davis, California. UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California.
authors: Christopher P
authors: CP
authors: Evans
authors: Department of Urology, University of California, Davis, California. Graduate Program in Pharmacology and Toxicology, University of California, Davis, Davis, California. UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California. acgao@ucdavis.edu.
authors: Allen C
authors: AC
authors: Gao
mesh_terms: D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000074425:Aldo-Keto Reductase Family 1 Member C3; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019898:Autocrine Communication; D001549:Benzamides; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D004789:Enzyme Activation; D057809:HEK293 Cells; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D016513:Mice, SCID; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013739:Testosterone / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; D013739:Testosterone; C540278:enzalutamide; D015096:3-Hydroxysteroid Dehydrogenases; D006911:Hydroxyprostaglandin Dehydrogenases; C487341:AKR1C3 protein, human; D000074425:Aldo-Keto Reductase Family 1 Member C3; D007213:Indomethacin
references: Cancer Res. 2013 Jan 15;73(2):483-9
references: 23117885
references: Eur Urol. 2015 Jan;67(1):53-60
references: 24882673
references: Sci Rep. 2013;3:1528
references: 23524847
references: Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
references: 16199517
references: Cancer Res. 2006 Mar 1;66(5):2815-25
references: 16510604
references: Cancer Discov. 2013 Sep;3(9):1030-43
references: 23842682
references: J Invest Dermatol. 2014 May;134(5):1397-407
references: 24213373
references: Clin Cancer Res. 2013 Oct 15;19(20):5613-25
references: 23995860
references: Clin Cancer Res. 2011 Sep 15;17(18):5913-25
references: 21807635
references: Cancer Res. 2011 Feb 15;71(4):1486-96
references: 21303972
references: N Engl J Med. 2012 Sep 27;367(13):1187-97
references: 22894553
references: J Med Chem. 2013 Mar 28;56(6):2429-46
references: 23432095
references: Clin Cancer Res. 2014 Nov 1;20(21):5547-57
references: 24771644
references: Cancer Res. 2012 Jul 15;72(14):3457-62
references: 22710436
references: Br J Cancer. 2014 Sep 23;111(7):1249-54
references: 24867689
references: Cancer Res. 2008 Aug 1;68(15):6407-15
references: 18676866
references: Cancer Res. 2012 Dec 1;72(23):6142-52
references: 22971343
references: Endocr Relat Cancer. 2014 Jun;21(3):435-42
references: 24659479
references: Steroids. 1997 Jan;62(1):148-58
references: 9029730
references: Cell. 2013 Dec 5;155(6):1309-22
references: 24315100
references: Cancer Discov. 2013 Sep;3(9):1020-9
references: 23779130
references: N Engl J Med. 2014 Sep 11;371(11):1028-38
references: 25184630
references: Clin Cancer Res. 2014 Jun 15;20(12):3198-210
references: 24740322
references: Biochem J. 2012 Apr 15;443(2):379-86
references: 22268531
references: PLoS One. 2012;7(8):e43965
references: 22937138
references: Anal Chem. 2013 May 21;85(10):4951-60
references: 23597399
references: Prostate. 2014 Feb;74(2):201-9
references: 24307657
references: Mol Cancer Ther. 2013 Sep;12(9):1829-36
references: 23861346
references: Cell. 2013 Aug 29;154(5):1074-84
references: 23993097
references: J Clin Pathol. 2008 Apr;61(4):448-54
references: 17720776
references: N Engl J Med. 2011 May 26;364(21):1995-2005
references: 21612468
references: N Engl J Med. 2013 Jan 10;368(2):138-48
references: 23228172
references: Oncogene. 2014 Sep 4;33(36):4521-30
references: 24662833
references: Mol Endocrinol. 2006 Feb;20(2):444-58
references: 16179381
references: Genes Cancer. 2011 Feb;2(2):151-9
references: 21779488
references: Lancet. 2010 Apr 24;375(9724):1437-46
references: 20398925
references: Horm Cancer. 2014 Apr;5(2):72-89
references: 24615402
references: Cancer Res. 2008 Jun 1;68(11):4447-54
references: 18519708
references: Mol Cancer Ther. 2013 Aug;12(8):1629-37
references: 23699654
references: Cancer Res. 2008 Jul 1;68(13):5469-77
references: 18593950
references: Cancer Res. 2011 Oct 15;71(20):6503-13
references: 21868758